{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:44:43Z","timestamp":1790995483499,"version":"4.1.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>It is an understatement to say that drug approvals in systemic lupus erythematosus (SLE), lupus nephritis, and Sjogren's syndrome have lagged far behind those in other autoimmune diseases, such as rheumatoid arthritis and psoriatic arthritis. Reasons for this are multiple and include the molecular and clinical heterogeneity of these conditions; confounding by background medications, especially corticosteroids; and clinical trial endpoints. However, the tides are changing, and there have been several bright spots in our attempts to bring more efficacious drugs to our patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Several positive phase II and phase III trials in SLE and lupus nephritis with drugs such as anifrolumab, voclosporin, belimumab, and obinutuzumab will no doubt eventually generate regulatory approvals for most, if not all, of these drugs. Although early in development, the promising results in Sjogren's syndrome with iscalimab and ianalumab should make the Sjogren's syndrome community quite hopeful of future drug approvals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>In this review, we highlight recent study results in Sjogren's syndrome, SLE, and lupus nephritis, emphasizing investigational therapies in late stage development, but we also provide a glimpse into drugs of the future.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000754","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:10:41Z","timestamp":1601424641000},"page":"609-616","source":"Crossref","is-referenced-by-count":20,"title":["Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis"],"prefix":"10.1097","volume":"32","author":[{"given":"Sonali","family":"Narain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"issue":"(Suppl 10)","key":"R1-20230829","article-title":"A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis [abstract]","volume":"71","author":"Furie","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"102364","DOI":"10.1016\/j.jaut.2019.102364","article-title":"Sjogren's syndrome: old and new therapeutic targets","volume":"110","author":"Mavragani","year":"2020","journal-title":"J Autoimmun"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R6-20230829","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 2)","key":"R10-20230829","first-page":"89","article-title":"OP0039 efficacy and safety of abatacept in active primary Sj\u00f6gren's syndrome: results of a randomised placebo-controlled phase III trial","volume":"78","author":"Baer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"(suppl 1)","key":"R12-20230829","first-page":"102","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren's syndrome: open-label extension phase of a randomized controlled phase III trial","volume":"79","author":"Arends","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 10)","key":"R13-20230829","article-title":"IL-6 receptor inhibition in primary Sj\u00f6gren syndrome: results from a randomized multicenter academic double blind placebo-controlled trial of tocilizumab in 110 patients","volume":"71","author":"Felten","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"(suppl 1)","key":"R14-20230829","first-page":"187","article-title":"Ianalumab (VAY736), a dual mode of action biologic combining BAFF receptor inhibition with B cell depletion, reaches primary endpoint for treatment of primary Sjogren's syndrome","volume":"79","author":"D\u00f6rner","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"(Suppl 1)","key":"R16-20230829","first-page":"A149","article-title":"200 Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the EMBRACE study","volume":"6","author":"D\u2019Cruz","year":"2019","journal-title":"Lupus Sci Med"},{"issue":"(Suppl 10)","key":"R17-20230829","article-title":"Efficacy of belimumab in patients of black race with systemic lupus erythematosus and high disease activity or renal manifestations","volume":"71","author":"Sergio Guedes Barbosa","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 2)","key":"R19-20230829","first-page":"764","article-title":"FRI0181 the PLUTO study: intravenous belimumab in children with systemic lupus erythematosus","volume":"78","author":"Ruperto","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/art.40439","article-title":"Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of a seventy-six-week phase III parent study in the United States","volume":"70","author":"Furie","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.40861","article-title":"Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus","volume":"71","author":"Wallace","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"(Suppl 10)","key":"R22-20230829","article-title":"A human recombinant fusion protein targeting B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL), telitacicept (RC18), in systemic lupus erythematosus (SLE): results of a phase 2b study","volume":"71","author":"Wu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"E208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/annrheumdis-2019-216379","article-title":"IFN-alpha kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study","volume":"79","author":"Houssiau","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"464","DOI":"10.15252\/emmm.201404719","article-title":"Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms","volume":"7","author":"Pellerin","year":"2015","journal-title":"EMBO Mol Med"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J Clin Invest"},{"issue":"(Suppl 1)","key":"R29-20230829","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/annrheumdis-2020-eular.5743","article-title":"OP0193 BIIB059, a humanized monoclonal antibody targeting BDCA2 on plasmacytoid dendritic cells (PDC), shows dose-related efficacy in the phase 2 lilac study in patients (pts) with active cutaneous lupus erythematosus (CLE)","volume":"79","author":"Werth","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"e90424","DOI":"10.1371\/journal.pone.0090424","article-title":"Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis","volume":"9","author":"Dema","year":"2014","journal-title":"PLoS One"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.40828","article-title":"Safety and tolerability of omalizumab: a randomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus","volume":"71","author":"Hasni","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1586\/1744666X.2014.893827","article-title":"The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets","volume":"10","author":"Shao","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"(Suppl 10)","key":"R34-20230829","first-page":"100","article-title":"Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor, fenebrutinib (GDC-0853), in moderate to severe systemic lupus erythematosus: results of a phase 2 randomized controlled trial","volume":"71","author":"Isenberg","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.41179","article-title":"Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"(Suppl 2)","key":"R37-20230829","first-page":"220","article-title":"OP0278 biomarker profiling reveals novel mechanistic insights into ustekinumab therapeutic responses in systemic lupus erythematosus","volume":"78","author":"Cesaroni","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 1)","key":"R38-20230829","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2020-eular.2407","article-title":"OP0161 association of baseline cytotoxic gene expression with ustekinumab response in systemic lupus erythematosus","volume":"79","author":"Seridi","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 10)","key":"R39-20230829","article-title":"Efficacy and safety of dapirolizumab pegol in patients with moderately to severely active systemic lupus erythematosus: a randomized, placebo-controlled study","volume":"71","author":"Furie","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/art.40479","article-title":"Brief report: a randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG 557 in patients with systemic lupus erythematosus and active lupus arthritis","volume":"70","author":"Cheng","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4 (+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 1)","key":"R45-20230829","first-page":"234","article-title":"NKTR-358, a novel IL-2 conjugate, stimulates high levels of regulatory T cells in patients with systemic lupus erythematosus","volume":"79","author":"Siddhanti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/0961203317717083","article-title":"Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men","volume":"27","author":"Schwarting","year":"2018","journal-title":"Lupus"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.4049\/jimmunol.1600281","article-title":"BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis","volume":"198","author":"Kang","year":"2017","journal-title":"J Immunol"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5414\/CN109325","article-title":"Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus","volume":"89","author":"Yang","year":"2018","journal-title":"Clin Nephrol"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1523-1755.2005.00461.x","article-title":"Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study","volume":"68","author":"Mok","year":"2005","journal-title":"Kidney Int"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R53-20230829","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R55-20230829","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary nonresponse to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology"},{"key":"R58-20230829","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"(suppl 10)","key":"R59-20230829","article-title":"Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis","volume":"70","author":"Dall\u2019Era","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R60-20230829","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R61-20230829","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.molimm.2007.04.029","article-title":"Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis","volume":"45","author":"Fiore","year":"2008","journal-title":"Mol Immunol"},{"key":"R62-20230829","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/art.22044","article-title":"Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus","volume":"54","author":"Feng","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:15:43Z","timestamp":1693293343000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000754","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]}}}